

# Research Grade Motavizumab

## Summary

---

<b>Catalog No.</b>	DVV02803
<b>Alternative Names</b>	MEDI-524, NUMAX, NISTmAb, CR9503, CAS: 677010-34-3
<b>Clone ID</b>	Motavizumab
<b>Host species</b>	Humanized
<b>Species reactivity</b>	HRSV-A
<b>Form</b>	Liquid
<b>Storage buffer</b>	0.01M PBS, pH 7.4.
<b>Concentration</b>	1 mg/ml
<b>Purity</b>	>95% as determined by SDS-PAGE.
<b>Clonality</b>	Monoclonal
<b>Isotype</b>	IgG1, kappa
<b>Applications</b>	Research Grade Biosimilar
<b>Target</b>	F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1
<b>Purification</b>	Protein A/G purified from cell culture supernatant.
<b>Endotoxin level</b>	Please contact with the lab for this information.
<b>Expression system</b>	Mammalian Cells
<b>Accession</b>	P03420

**Stability and Storage**

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.


**Note**

For research use only. Not suitable for clinical or therapeutic use.

## Description

Motavizumab (MEDI-524, NUMAX, NISTmAb) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis. It has been evaluated in large-scale clinical studies, and has demonstrated efficacy in reducing the disease burden of RSV in high-risk infant populations. Motavizumab (MEDI-524, NUMAX, NISTmAb) has higher affinity and a longer half-life, was effective in reducing RSV hospitalization in high-risk full-term infants in the US, but was not licensed due to safety concerns (allergic reactions) .


## Data Image



SDS-PAGE

SDS PAGE for Motavizumab


Motavizumab binds with RSV glycoprotein F0



Bioactivity

Detects F/Fusion glycoprotein F0 in indirect ELISAs.


Motavizumab binds with HRSV-A2 Pre-F



Bioactivity


Detects HRSV-A2 Pre-F/Fusion glycoprotein F0 Protein in indirect ELISA.

Motavizumab binds with HRSV Post-F




Bioactivity

Detects HRSV Post-F/Fusion glycoprotein F0 Protein in indirect ELISA.



Detects HRSV F/Fusion glycoprotein F0 Protein in indirect ELISA.



The purity of this product is >95% as determined by SEC-HPLC.